Luminous Ventures

Lomax Ward serves as General Partner and leads investment decisions. Prior to Luminous, Ward operated in the health-tech space as an entrepreneur, which informs the firm's posture of evaluating scientific founders as peer operators rather than purely financial sponsors. The firm has not disclosed additional GPs or an investment committee structure.

Luminous targets pre-seed and seed rounds, typically writing first cheques in the £500,000 to £2 million range. The firm prefers to lead or co-lead rounds where it can secure board exposure and work closely with founding scientists during the commercial translation phase.

The firm's mandate is weighted toward frontier technology — synthetic biology, precision medicine, advanced computing — but it does back software where the code addresses a deep-tech vertical. Orbital Witness, a legal-tech platform applying machine learning to real estate due diligence, sits in the portfolio alongside life-science companies, demonstrating flexibility at the application layer.

Luminous concentrates on the United Kingdom, particularly the golden-triangle universities of Oxford, Cambridge, and London, and extends selectively into Nordic deep-tech hubs. The firm sources through principal investigators and technology-transfer offices rather than relying on the generalist European accelerator circuit.

Deal flow is built on relationships with academic researchers, postdoctoral labs, and university technology-transfer offices. By evaluating published papers, filed patents, and bench strength as primary due-diligence inputs, the firm accesses startups that often have not yet appeared on demo-day stages or generalist VC radar.